CLinicaL appLication of Liver stiffness measurement in patients with cavernous transformation of portaL vein

Abstract

Abstract: Objective To evaLuate Liver cirrhosis in patients with cavernous transformation of portaL vein (CTPV) by measurement of Liver stiffness measurement (LSM) using transient eLastography. Methods From January 2012 to ApriL 2021, 22 CTPV patients (12 maLes and 10 femaLes) with an age of (50.2±11.8) years were reviewed. MeanwhiLe, 30 patients with chronic hepatitis B reLated cirrhosis were selected as control group. t-test or Mann-Whitney U-test was used for measurement data, and Chi-square test was used for counting data. Results Comparing the cLinicaL data of CTPV patients (CTPV group) and controL group, ALT, AST and ALP in CTPV group were 36 (22, 52), 38 (26, 56)and 71 (52, 92) U/L, which were significantly higher than those in control group [19 (14, 31), 26(19, 42) and 88(72, 116)U/L, P<0.05]. The LSM of CTPV group and control group were 12.6(6.8, 21.4) and 21.2(15.4, 26.8) kPa, the difference was statistically significant (P<0.05). The staging of liver fibrosis in CTPV group was 8 (36.4%), 2 (9.1%) and 12 cases (54.5%), while that in control group was 0(0), 0(0) and 30(100), the difference was statistically significant (P<0.05). Comparing the data of CTPV patients with cirrhosis (cirrhosis group) and without cirrhosis (non-cirrhosis group), the ages of cirrhosis group and non-cirrhosis group were (56.2±13.8) and (44.1±9.7) years, and the difference was statistically significant (P<0.05). The Alb of cirrhosis group and non-cirrhosis group were 35.0(35.0, 40.2) and 39.6(38.2, 42.7) g/L, with statistical significance (P<0.05). The HBsAg in cirrhosis group and non-cirrhosis group was 9 (75.0%) and 2(20.0%), with statistical significance (P<0.05). HVPG in cirrhotic group and non-cirrhotic group was 16.8(13.2, 22.0) and 6.4(5.0, 9.8) mmHg, the difference was statistically significant (P<0.05). The LSM of cirrhosis group and non-cirrhosis group were 17.6(6.8, 29.5) and 6.8(5.3, 8.2) kPa, with statistical significance (P<0.05). Conclusion The LSM value of CTPV patients is significantly different from that of chronic hepatitis B-related cirrhosis, and the LSM value of CTPV patients with cirrhosis is significantly higher than that of patients without cirrhosis. Transient elastography can effectively evaluate the cirrhosis of CTPV patients.

Key words: Cavernous transformation of portal vein, Liver stiffness measurement, Liver cirrhosis

SHI Tai-ying, HAN Hua, LI Jian-Ling. CLinicaL appLication of Liver stiffness measurement in patients with cavernous transformation of portaL vein[J]. Chinese Hepatolgy, 2021, 26(12): 1401-1403.

References

[1] Zhang YQ, Wang Q, Wu M, et al. Sonographic features of umbilical vein recanalization for a Rex shunt on cavernous transformation of portal vein in children. World J Clin Cases, 2020, 8:5555-5563.
[2] Shen Y, Yao Y, Wang Y, et al. Obstructive jaundice caused by postsplenectomy cavernous transformation of the portal vein mimicking cholangiocarcinoma. Gastrointest Endosc, 2020, 92:786-787.
[3] Li LN, Sun XY, Wang GC, et al. Transjugular intrahepatic portosystemic shunt prevents rebleeding in cirrhotic patients having cavernous transformation of the portal vein without improving their survival. J Dig Dis, 2019, 20:89-96.
[4] Ruan Z, Wu M, Shao C, et al. Effects of Rex-bypass shunt on the cavernous transformation of the portal vein in children: evaluation by the color Doppler ultrasonography. Insights Imaging, 2020, 11:4.
[5] Hwang M, Thimm MA, Guerrerio Al. Detection of cavernous transformation of the portal vein by contrast-enhanced ultrasound. J Ultrasound, 2018, 21:153-157.
[6] Zhang MM, Pu CL, Li YC, et al. Sixty-four-slice computed tomography in surgical strategy of portal vein cavernous transformation. World J Gastroenterol, 2011, 17:4334-4338.
[7] Eddowes PJ, Sasso M, Allison M, et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology, 2019, 156:1717-1730.
[8] Cassinotto C, Boursier J, de Lédinghen V, et al. Liver stiffness in nonalcoholic fatty liver disease: A comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy. Hepatology, 2016, 63:1817-1827.
[9] Kwok R, Choi KC, Wong GL, et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut, 2016, 65:1359-1368.
[10] Boursier J, Vergniol J, Guillet A, et al. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. J Hepatol, 2016, 65:570-578.
[11] Sharma P, Mishra SR, Kumar M, et al. Liver and spleen stiffness in patients with extrahepatic portal vein obstruction. Radiology, 2012, 263:893-899.
[12] Shen Y, Ma W, Hang Y, et al. Clinical application of liver stiffness measurement in patients with cavernous transformation of portal vein. Exp Ther Med, 2021, 21:442.
[13] Ma Y, Dong D, Gong Z, et al. Novel imaging-based approaches for predicting the hepatic venous pressure gradient in a porcine model of liver cirrhosis and portal hypertension. Life Sci, 2021, 264:118710.
[14] Wang T, Liang F, Li L, et al. A computational model-based study on the exchangeability of hepatic venous pressure gradients measured in multiple hepatic veins. Med Eng Phys, 2020, 84:28-35.
[15] Lin JY, Zhang CH, Zheng L, et al. Establishment and assessment of the hepatic venous pressure gradient using biofluid mechanics (HVPGBFM): protocol for a prospective, randomised, non-controlled, multicentre study. BMJ Open, 2019, 9:e028518.